Ascendis Pharma (ASND) Price & Analysis

Compare

592 Followers

ASND Stock Chart & Stats

Day’s Range― - ―

52-Week Range$111.09 - $183.00

Previous CloseN/A

Volume129.18K

Average Volume (3M)396.94K

Market Cap

$10.44B

Enterprise Value$6.46B

Total Cash (Recent Filing)$559.54M

Total Debt (Recent Filing)€856.62M

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Sep 09, 2025

EPS Estimate

-1.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.82

Shares Outstanding60,970,566

10 Day Avg. Volume360,046

30 Day Avg. Volume396,937

Financial Highlights & Ratios

PEG Ratio-0.23

Price to Book (P/B)24.28

Price to Sales (P/S)0.00

P/FCF Ratio-12.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$222.85

Price Target Upside28.82% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Ascendis Pharma News

See All ASND News

See All News >

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst reiterates a Buy with an updated $216 PO and highlights ASND as one of the top picks of 2025.

Clinical Trial ResultsThe combination of TransCon hGH and CNP in achondroplasia demonstrated the potential to boost growth significantly above that observed with CNP monotherapy, which could significantly alter the treatment paradigm.

Market PotentialThe expansion to additional indications provides potential for increased market share and commercial competitiveness for TransCon CNP.

Bears Say

Legal RisksBMRN IP litigation overhang limits investors assigning more credit for TransCon CNP.

Regulatory ChallengesDespite forward regulatory progress and differentiating data, Ascendis Pharma's CNP program remains underappreciated and is a strong source of potential growth.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

―

Insiders

31.64% Mutual Funds

0.15% Other Institutional Investors

67.11% Public Companies and Individual Investors

Detailed Ownership Overview >

ASND FAQ

What was Ascendis Pharma A/S’s price range in the past 12 months?

Ascendis Pharma A/S lowest stock price was $111.09 and its highest was $183.00 in the past 12 months.

What is Ascendis Pharma A/S’s market cap?

Ascendis Pharma A/S’s market cap is $10.44B.

When is Ascendis Pharma A/S’s upcoming earnings report date?

Ascendis Pharma A/S’s upcoming earnings report date is Sep 09, 2025 which is in 74 days.

How were Ascendis Pharma A/S’s earnings last quarter?

Ascendis Pharma A/S released its earnings results on May 01, 2025. The company reported -$1.825 earnings per share for the quarter, missing the consensus estimate of -$1.694 by -$0.131.

Is Ascendis Pharma A/S overvalued?

According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ascendis Pharma A/S pay dividends?

Ascendis Pharma A/S does not currently pay dividends.

What is Ascendis Pharma A/S’s EPS estimate?

Ascendis Pharma A/S’s EPS estimate is -1.57.

How many shares outstanding does Ascendis Pharma A/S have?

Ascendis Pharma A/S has 60,970,566 shares outstanding.

What happened to Ascendis Pharma A/S’s price movement after its last earnings report?

Ascendis Pharma A/S reported an EPS of -$1.825 in its last earnings report, missing expectations of -$1.694. Following the earnings report the stock price went up 2.741%.

Which hedge fund is a major shareholder of Ascendis Pharma A/S?

Currently, no hedge funds are holding shares in ASND

Ascendis Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

357.68%

Trailing 12-Months

Asset Growth

32.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ascendis Pharma A/S

Ascendis Pharma A/S (ASND) is a biopharmaceutical company focused on improving patient outcomes through the development of innovative therapies. The company operates primarily in the healthcare sector, specializing in endocrinology and oncology. Its core products include TransCon growth hormone for pediatric growth hormone deficiency, and the company is also exploring treatments in other therapeutic areas using its proprietary TransCon technology platform, which allows for sustained release of drugs to improve efficacy and patient experience.

ASND Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlights Ascendis Pharma's strong launch and revenue growth for YORVIPATH, alongside significant advances in their product pipeline. However, this success is tempered by increased operating expenses and ongoing challenges in securing insurance reimbursements. Overall, the sentiment is balanced with significant achievements and operational challenges.Read More>

ASND Stock 12 Month Forecast

Average Price Target

$222.85

▲(28.82%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","207":"$207","290":"$290","165.5":"$165.5","248.5":"$248.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":289,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$289.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":222.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$222.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":194,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$194.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,165.5,207,248.5,290],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.69,184.40615384615384,193.1223076923077,201.83846153846153,210.55461538461537,219.27076923076922,227.98692307692306,236.70307692307694,245.41923076923075,254.13538461538462,262.85153846153844,271.5676923076923,280.2838461538462,{"y":289,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.69,179.3176923076923,182.94538461538463,186.5730769230769,190.20076923076923,193.82846153846154,197.45615384615385,201.08384615384614,204.71153846153845,208.33923076923077,211.96692307692308,215.5946153846154,219.22230769230768,{"y":222.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.69,177.09846153846155,178.50692307692307,179.91538461538462,181.32384615384615,182.7323076923077,184.14076923076922,185.54923076923077,186.9576923076923,188.36615384615385,189.77461538461537,191.18307692307692,192.59153846153845,{"y":194,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":135.1,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.98,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.53,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >